Equities

Arch Biopartners Inc

ARCH:CVE

Arch Biopartners Inc

Actions
  • Price (CAD)2.05
  • Today's Change0.08 / 4.06%
  • Shares traded63.09k
  • 1 Year change+102.97%
  • Beta0.9468
Data delayed at least 15 minutes, as of Nov 08 2024 20:56 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform0
Hold1
Sell0
Strong Sell0

Share price forecast in CAD

The one analyst offering a 12 month price target expects Arch Biopartners Inc share price to rise to 3.50 in the next year from the last price of 2.05.
High70.7%3.50
Med70.7%3.50
Low70.7%3.50

Earnings history & estimates in CAD

On Aug 28, 2024, Arch Biopartners Inc reported 3rd quarter 2024 losses of -0.014 per share. This result was in line with the expectation of the one analyst following the company and under-performed last year's 3rd quarter results by -0.007.
Average growth rate+37.78%
Arch Biopartners Inc reported annual 2023 losses of -0.053 per share on Jan 28, 2024.
Average growth rate-165.00%
More ▼

Revenue history & estimates in CAD

of 116.00k.
Average growth rate+193.21%
Arch Biopartners Inc. had revenues for the full year 2023 of 1.98m. This was 105.60% above the prior year's results.
Average growth rate+105.60%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.